TEL AVIV, Israel, February 7, 2017 /PRNewswire/ --
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage
biopharmaceutical company focused on oncology and immunology,
announced today that its Chief Executive Officer, Philip Serlin, and its Chief Business Officer,
David Malek, will present a company
update at the 2016 BIO CEO & Investor Conference on
Tuesday, February 14, 2017 at
10:30 am EST. The conference will be
held at the Waldorf Astoria Hotel in New
York.
A live webcast of the presentation will be available on
BioLineRx's website. A replay will be available one hour after the
presentation ends and will be accessible for three months following
the presentation.
Investors or potential partners attending the conference who
wish to meet with BioLineRx management should contact the BIO
Partnering Team at biopartnering@bio.org.
About BioLineRx
BioLineRx is a clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds,
primarily from academic institutions and biotech companies based in
Israel, develops them through
pre-clinical and/or clinical stages, and then partners with
pharmaceutical companies for advanced clinical development and/or
commercialization.
BioLineRx's leading therapeutic candidates are: BL-8040, a
cancer therapy platform, which has successfully completed a Phase
2a study for relapsed/refractory AML and is in the midst of a Phase
2b study as an AML consolidation treatment and a Phase 2 study in
stem cell mobilization for allogeneic transplantation; and BL-7010
for celiac disease and gluten sensitivity, which has successfully
completed a Phase 1/2 study. In addition, BioLineRx has a strategic
collaboration with Novartis for the co-development of selected
Israeli-sourced novel drug candidates; a collaboration agreement
with MSD (known as Merck in the US and Canada), on the basis of which the Company has
initiated a Phase 2a study in pancreatic cancer using the
combination of BL-8040 and Merck's KEYTRUDA®; and a
collaboration agreement with Genentech, a member of the Roche
Group, to investigate the combination of BL-8040 and Genentech's
Atezolizumab in several Phase 1b studies for multiple solid tumor
indications and AML.
For additional information on BioLineRx, please visit the
Company's website at www.biolinerx.com, where you can review
the Company's SEC filings, press releases, announcements and
events. BioLineRx industry updates are also regularly updated
on Facebook, Twitter, and LinkedIn.
Contacts for BioLineRx:
PCG Advisory
Vivian Cervantes
Investor Relations
212-554-5482
vivian@pcgadvisory.com
or
Tsipi Haitovsky
Public Relations
+972-3-624-0871
tsipihai5@gmail.com
SOURCE BioLineRx Ltd.